Sotevtamab, CAS 2411526-47-9

Product Description: Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467. /[2]Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098. /[3]Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.

CAS Number: 2411526-47-9

Molecular Weight: N/A

Compound Purity: 99.67

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Apoptosis

• Artikelnummer: MEXHY-P99589-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99589-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated